NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART TO ANY PERSON OR ADDRESS IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.
Hikma prices debut $500 million five-year eurobond
London, April 1, 2015: Hikma Pharmaceuticals PLC, the multinational pharmaceutical group (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), today announces that it has successfully priced a Reg S $500 million 4.25% eurobond due April 2020. The proceeds will be used to refinance existing debt and for general corporate purposes. The bond will be listed on the Global Exchange Market of the Irish Stock Exchange. FCA/ICMA stabilisation applies.
The joint lead managers were Citi (Global Coordinator), Barclays, HSBC and National Bank of Abu Dhabi.
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2770/ +44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/ +44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/ +44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
A RATING IS NOT A RECOMMENDATION TO BUY, SELL OR HOLD SECURITIES AND MAY BE SUBJECT TO REVISION, SUSPENSION OR WITHDRAWAL AT ANY TIME BY THE ASSIGNING RATING ORGANISATION. SIMILAR RATINGS FOR DIFFERENT TYPES OF ISSUERS AND ON DIFFERENT TYPES OF SECURITIES DO NOT NECESSARILY MEAN THE SAME THING. THE SIGNIFICANCE OF EACH RATING SHOULD BE ANALYSED INDEPENDENTLY FROM ANY OTHER RATING.
NOTHING IN THIS ANNOUNCEMENT CONSTITUTES AN OFFER OF SECURITIES FOR SALE, OR A SOLICITATION OF AN OFFER TO BUY SECURITIES, NOR SHALL THERE BE ANY SALE OF SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE SECURITIES TO WHICH THIS ANNOUNCEMENT RELATES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, SUBJECT TO CERTAIN EXCEPTIONS, MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES.
This announcement is only addressed to and directed at persons in member states of the European Economic Area who are qualified investors (as defined in Directive 2003/71/EC, as amended (the "Prospectus Directive")). This announcement has not been approved by the UK Financial Conduct Authority. This announcement is not being distributed to, and must not be passed on to, the general public in the United Kingdom. Rather, this announcement is being distributed on the basis that it is only being distributed to and is only directed at: (i) persons who are Investment Professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order"); (ii) persons falling within any of the categories of persons described in Article 49 of the Financial Promotion Order; and (iii) any other person to whom it may otherwise lawfully be made in accordance with the Financial Promotion Order (all such person together referred to as "relevant persons"). Any security, investment or investment activity to which this announcement may relate is only available to, and any invitation, offer, or agreement to engage in such investment activity will be engaged in only with: (i) in the United Kingdom, relevant persons; and (ii) in any member state of the European Economic Area other than the United Kingdom, qualified investors. No other person should rely on it or any of its contents. This announcement is an advertisement and is not a prospectus for the purposes of the Prospectus Directive.
This announcement does not constitute or form a part of any offer of, or solicitation to purchase, securities in the Kingdom of Saudi Arabia. There will be no public offer of securities in the Kingdom of Saudi Arabia.
--ENDS -
